ORPHELIA Pharma is a biopharmaceutical company dedicated to improving the health and well-being of severely disabled children.
We strive to bring to the market innovative drugs targeting CNS and metabolic diseases.


Discover our pipeline


ORP-001

ORP-001 is a reformulation of the antiepileptic
drug vigabatrin which makes its administration to young
patients easier and safer too. The clinical evaluation
(SoluWest) is completed.
Click to visit

ORP-002

ORP-002 is a drug developped in Rett syndrome, a debilitating condition for which no treatments are available. This program has obtained an Orphan Drug Designation (EU/3/09/643) from the EMA.
Click to visit

ORP-003

ORP-003 is a reformulation of an existing antiepileptic drug to make it easier and safer to administer to children and expand its current authorized indications.
Click to visit

ORP-006

ORP-006 is a drug that targets an orphan form of a neonatal epileptic encephalopathy. The dosage form developed is a new enteral/parenteral formulation which could be used for neonates, children and adults.
Click to visit